Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 10/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | GMPS | P49915 | 1/20 | 0.52 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 2/20 | 0.50 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30180733 | 1.00 | NR4A2 (0.59) | NR4A2KMT2ANPC1RAB9AAKR1C3 | |
| SCHEMBL16789662 | 0.85 | PARP1 (0.56) | MAOBGMPS | |
| SCHEMBL9154356 | 0.85 | MAOB (0.59) | KMT2AMAOBGMPS | |
| SCHEMBL20704575 | 0.85 | GMPS (0.54) | NR4A2KMT2ANPC1RAB9AMAOB | |
| SCHEMBL30382600 | 0.85 | NR4A2 (0.61) | NR4A2KMT2ANPC1RAB9AAKR1C3 | |
| SCHEMBL9126675 | 0.85 | NR4A2 (0.61) | NR4A2KMT2ANPC1RAB9AAKR1C3 | |
| SCHEMBL10774877 | 0.85 | NR4A2 (0.61) | NR4A2KMT2ANPC1RAB9AAKR1C3 | |
| SCHEMBL30640594 | 0.83 | CYP19A1 (0.57) | RAB9AMAOBMRGPRX4 | |
| SCHEMBL26673845 | 0.83 | CYP19A1 (0.57) | RAB9AMAOBMRGPRX4 | |
| SCHEMBL30180651 | 0.83 | MRGPRX4 (0.52) | KMT2ANPC1RAB9AMAOBGMPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257041-A1 | INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-08-14 | — | — | US | disclosed |
| US-20250101007-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| US-12258332-B2 | ASGPR cell surface receptor binding compounds and conjugates | LYCIA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240287492-A1 | BIFUNCTIONAL CHEMICAL EPIGENENTIC MODIFIERS AND METHODS OF USE | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2024-08-29 | — | — | US | disclosed |
| EP-4370157-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-117957020-A | ASGPR cell surface receptor binding compounds and conjugates | 利西亚治疗公司 | 2024-04-30 | — | — | CN | disclosed |
| US-11905537-B2 | Bifunction chemical epigenetic modifiers and methods of use | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-02-20 | — | — | US | disclosed |
| CN-113603684-B | 1,2, 4-oxadiazole Nrf2 activator-tac Lin Pinge product and preparation method and application thereof | 中国药科大学 | 2023-12-19 | — | — | CN | disclosed |
| WO-2023225327-A1 | INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| EP-1986694-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | Novo Nordisk A/S (DK) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093594-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (DK) | 2007-08-23 | — | — | WO | disclosed |
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | WYETH (US) | 2005-02-10 | — | — | US | disclosed |
| US-5104881-A | 2-ARYLIMIDAZOPYRIDINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1992-04-14 | — | — | US | disclosed |
| US-4654344-A | ALSO AFFECT BLOOD PRESSURE AND MYOCARDIAL CONTRACTIONS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1987-03-31 | — | — | US | disclosed |
| US-4616090-A | 2-arylimidazopyridines intermediates | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1986-10-07 | — | — | US | disclosed |
| EP-0072926-B1 | 2-ARYLIMIDAZOPYRIDINES | MERCK PATENT GmbH (DE) | 1986-09-24 | — | — | EP | disclosed |
| US-4575505-A | Pharmaceutical compositions containing 2-aryltetraazaindenes for treating ulcers or cardiac insufficiency or blood pressure abnormalities | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1986-03-11 | — | — | US | disclosed |
| US-4477454-A | INDOTROPIC AGENTS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-10-16 | — | — | US | disclosed |
| EP-0072926-A1 | 2-Arylimidazopyridines | MERCK PATENT GmbH (DE) | 1983-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287492-A1 | BIFUNCTIONAL CHEMICAL EPIGENENTIC MODIFIERS AND METHODS OF USE | DNMT1, HDAC2, HDAC1 | NR4A2 919/4885KMT2A 26/4885NPC1 4463/4885 |
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | TPH2, HTR2C, HTR7 | NR4A2 1360/4885KMT2A 1963/4885NPC1 4504/4885 |
| US-20250257041-A1 | INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER | DDIT3, ATF4, EIF2AK3 | NR4A2 1090/4885KMT2A 3590/4885NPC1 3571/4885 |
| US-12258332-B2 | ASGPR cell surface receptor binding compounds and conjugates | ASGR1, LAMP2, FCGR2A | NR4A2 2558/4885KMT2A 3976/4885NPC1 165/4885 |
| US-20250101007-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | NR4A2 2558/4885KMT2A 3976/4885NPC1 165/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | NR4A2 3020/4885KMT2A 3122/4885NPC1 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.